.July 26, 2024 05:44:00 AM

Dexcom (NASDAQ:DXCM) revised its guidance downward after second-quarter revenue missed expectations, leading to a 36% drop in pre-market shares. The company adjusted its revenue forecast to $4.00 billion to $4.05 billion, down from $4.20 billion to $4.35 billion. Despite progress on key initiatives, Dexcom admitted to falling short of execution standards. Second-quarter earnings were $0.43 per share on $1.00 billion revenue, below analysts’ expectations of $0.39 per share on $1.04 billion. For the third quarter, revenue guidance is $975 million to $1.00 billion, lower than the Street estimate of $1.15 billion.